Read More

Precigen To Present Late-Breaking Abstract For Pivotal Phase 2 Study Data For PRGN-2012 AdenoVerse Immunotherapy For The Treatment Of Patients With Recurrent Respiratory Papillomatosis At The 2024 ASCO Annual Meeting

Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical data from the pivotal Phase

PGEN

Read More

Cullinan Therapeutics To Present Clinical Data From Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, As Monotherapy And In Combination With A Checkpoint Inhibitor In Patients With Advanced Solid Tumors At ASCO 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid

CGEM

Read More

Autolus Therapeutics Announces Abstract For Longer-Term Follow-Up And Additional Data Analysis Of Pivotal Phase 2 FELIX Study Of obe-cel For Adult r/r B-ALL Selected For An Oral Presentation At ASCO

Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for longer-term follow-up and additional

AUTL